Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Acquires 24,760 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 24,760 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was bought at an average cost of $8.74 per share, with a total value of $216,402.40. Following the completion of the purchase, the director owned 17,697,436 shares of the company’s stock, valued at approximately $154,675,590.64. This represents a 0.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The shares were bought at an average price of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han acquired 5,990 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $7.45 per share, with a total value of $779,642.50.
• On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han bought 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.25 per share, with a total value of $1,942,500.00.

Burning Rock Biotech Stock Up 9.6%

BNR stock opened at $9.82 on Friday. The stock’s 50 day simple moving average is $12.57 and its 200 day simple moving average is $20.04. The company has a market cap of $103.31 million, a P/E ratio of -11.98 and a beta of 1.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.81 and a current ratio of 3.05. Burning Rock Biotech Limited Sponsored ADR has a fifty-two week low of $3.23 and a fifty-two week high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The firm had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BNR. Wall Street Zen downgraded shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Hedge Funds Weigh In On Burning Rock Biotech

A number of hedge funds have recently added to or reduced their stakes in BNR. Crcm LP increased its holdings in Burning Rock Biotech by 121.8% during the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after purchasing an additional 269,851 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after purchasing an additional 4,290 shares in the last quarter. Prospera Financial Services Inc lifted its holdings in shares of Burning Rock Biotech by 26.0% in the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after purchasing an additional 6,430 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Burning Rock Biotech during the fourth quarter valued at approximately $220,000. Institutional investors and hedge funds own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.